Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 9/20 | 0.48 |
| ▸ | JAK3 | P52333 | 7/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12904539 | 0.85 | STAT6 (0.58) | STAT6JAK3JAK2JAK1THRB | |
| SCHEMBL211691 | 0.85 | STAT6 (0.50) | STAT6JAK3JAK2JAK1THRB | |
| SCHEMBL210144 | 0.80 | PDE4B (0.48) | STAT6JAK3JAK2 | |
| SCHEMBL211406 | 0.78 | HDAC1 (0.63) | — | |
| SCHEMBL7126529 | 0.78 | JAK3 (0.58) | STAT6JAK3JAK2JAK1THRB | |
| SCHEMBL1522370 | 0.77 | PPARG (0.62) | STAT6THRBRXFP1 | |
| SCHEMBL445955 | 0.71 | ALDH1A1 (0.65) | SYK | |
| SCHEMBL12904999 | 0.71 | JAK2 (0.60) | STAT6JAK3JAK2JAK1SYK | |
| SCHEMBL1313173 | 0.71 | MAPK8 (0.58) | STAT6SYK | |
| SCHEMBL14456094 | 0.70 | AGTR1 (0.53) | STAT6JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | STAT6 2060/4885JAK3 2683/4885JAK2 1644/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | STAT6 1594/4885JAK3 2781/4885JAK2 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.